Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Exclusion Criteria

• - Patients who have been hospitalized for an acute COPD exacerbation within three months prior to Screening
• - Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the six weeks before Screening
• - Patients with any clinically significant respiratory conditions other than COPD
• - Clinical history that suggests that the patient has asthma as opposed to COPD
• - Chronic use of oxygen therapy ≥ 15 hours/day
• - Patients with clinically significant cardiovascular conditions
• - Patients with a history of hypersensitivity reaction to inhaled anticholinergics, beta-2 agonists, sympathomimetic amines, or inhaled medications